Phase II study for bevacizumab combined with S-1 and raltitrexed in the treatment of metastatic colorectal cancer resistant to 5-fluorouracil / oxaliplatin /irinotecan

ABSTRACT: Interventions: Case series:bevacizumab combined with S-1 and raltitrexed Primary outcome(s): ORR Study Design: Non randomized control

DISEASE(S): Metastatic Colorectal Cancer

PROVIDER: 2681508 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR